Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.
The NAFLD drugs in development market research report provides comprehensive information on the therapeutics under development for the NAFLD, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for NAFLD and features dormant and discontinued projects.
Key Targets in the NAFLD Pipeline Drugs Market
The key targets in the NAFLD pipeline drugs market are Glucagon Like Peptide 1 Receptor, Thyroid Hormone Receptor Beta, Glucagon Receptor, Peroxisome Proliferator Activated Receptor Alpha, Bile Acid Receptor, Diacylglycerol O Acyltransferase 2, Toll Like Receptor 4, Fibroblast Growth Factor Receptor 1 and others.
NAFLD Pipeline Drugs Market, by Target
For more target insights, download a free report sample
Key Mechanisms of Action in the NAFLD Pipeline Drugs Market
The key mechanisms of action in the NAFLD pipeline drugs market are Glucagon Like Peptide 1 Receptor Agonist, Thyroid Hormone Receptor Beta Agonist, Bile Acid Receptor Agonist, Toll Like Receptor 4 Antagonist, Acyl CoA Desaturase Inhibitor, Cannabinoid Receptor 1 Antagonist, and many others.
NAFLD Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free report sample
Key Routes of Administration in the NAFLD Pipeline Drugs Market
The key routes of administration in the NAFLD pipeline drugs market are intramuscular, vaginal, oral, parenteral, intravenous, subcutaneous, topical, and sublingual.
NAFLD Pipeline Drugs Market, by RoA
To get more insights on key RoA, download a free report sample
Key Molecule Types in the NAFLD Pipeline Drugs Market
The molecule types in the NAFLD pipeline drugs market are Small Molecule, Peptide, Recombinant Protein, Antisense Oligonucleotide, Biologic, Monoclonal Antibody, Recombinant Peptide, Synthetic Peptide, Fusion Protein, and Gene Therapy.
NAFLD Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free report sample
Major Companies in the Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Drugs Market
The major companies in the Non Alcoholic Fatty Liver Disease (NAFLD)pipeline drugs market are Pfizer Inc, Novartis AG, 89bio Inc, ABIONYX Pharma SA, Amgen Inc (Amgen), Ascletis Pharma Inc (Ascletis Pharma), AstraZeneca Plc, and Betagenon AB.
NAFLD Pipeline Drugs Market, by Company
For more company insights, download a free report sample
NAFLD Pipeline Drugs Market Overview
| Key targets | Glucagon Like Peptide 1 Receptor, Thyroid Hormone Receptor Beta, Glucagon Receptor, Peroxisome Proliferator Activated Receptor Alpha, Bile Acid Receptor, Diacylglycerol O Acyltransferase 2, Toll Like Receptor 4, Fibroblast Growth Factor Receptor 1 and Others |
| Key mechanisms of action | Glucagon Like Peptide 1 Receptor Agonist, Thyroid Hormone Receptor Beta Agonist, Bile Acid Receptor Agonist, Toll Like Receptor 4 Antagonist, Acyl CoA Desaturase Inhibitor, Cannabinoid Receptor 1 Antagonist, and Others |
| Key routes of administration | Intramuscular, Vaginal, Oral, Parenteral, Intravenous, Subcutaneous, Topical, and Sublingual |
| Key molecule types | Small Molecule, Peptide, Recombinant Protein, Antisense Oligonucleotide, Biologic, Monoclonal Antibody, Recombinant Peptide, Synthetic Peptide, Fusion Protein, and Gene Therapy |
| Key companies | Pfizer Inc, Novartis AG, 89bio Inc, ABIONYX Pharma SA, Amgen Inc (Amgen), Ascletis Pharma Inc (Ascletis Pharma), AstraZeneca Plc, and Betagenon AB |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD)therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
ABIONYX Pharma SA
Afimmune Biopharma Ltd
Agentix Corp
Albireo Pharma Inc
Alfasigma SpA
Altimmune Inc
Amgen Inc
Amicogen Inc
AptamiR Therapeutics Inc
Ascletis Pharma Inc
Asdera LLC
AstraZeneca Plc
AtoGen Co Ltd
BAR Pharmaceuticals Srl
Bast Biotechnology LLC
Bausch Health Companies Inc
Beijing FuKangren Bio-pharm Tech Co Ltd
Betagenon AB
Bird Rock Bio Inc
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
Chemomab Therapeutics Ltd
China NT Pharma Group Co Ltd
CohBar Inc
Corcept Therapeutics Inc
Corvidane
CVI Pharmaceuticals US Inc
Dr. Falk Pharma GmbH
DURECT Corp
Eli Lilly and Co
Enspire Bio Inc
Esperion Therapeutics Inc
Eternygen GmbH
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Fujian Cosunter Pharmaceutical Co Ltd
Future Medicine Co Ltd
Galmed Pharmaceuticals Ltd
GemVax & KAEL Co Ltd
GeneScience Pharmaceuticals Co Ltd
Gila Therapeutics Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HCW Biologics Inc
Hepion Pharmaceuticals Inc
HK inno.N Corp
HysensBio Corp
Immuron Ltd
Inmune Bio Inc
Inorbit Therapeutics AB
Inventiva SA
Ionis Pharmaceuticals Inc
J2H Biotech
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kaleido Biosciences Inc
Kinomedica Pty Ltd
KoBioLabs Inc
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
Liminal BioSciences Inc
Lipidio Pharmaceuticals Inc
Macrophage Pharma Ltd
Macrophage Therapeutics Inc
Madrigal Pharmaceuticals Inc
Metacrine Inc
Micelle BioPharma Inc
Mina Therapeutics Ltd
Nano Intelligent Biomedical Engineering Corp
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nivarta Inc
Novartis AG
NovMetaPharma Co Ltd
NovoBiome SAS
NuSirt Biopharma Inc
Oncocross Co Ltd
PegBio Co Ltd
Petri Bio LLC
Pfizer Inc
PharmaKing Co Ltd
Phenex Pharmaceuticals AG
Poxel SA
PTC Therapeutics Inc
Renova Therapeutics Inc
Sagimet Biosciences Inc
Salix Pharmaceuticals Ltd
Scohia Pharma Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
SparkBioPharma Inc
Sveikatal Inc
Synthetic Biologics Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
TES Pharma SRL
Theratechnologies Inc
Uni-Bio Science Group Ltd
Verseon Corp
VGI Health Technology Ltd
Vidasym Inc
Viking Therapeutics Inc
Zedira GmbH
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market?
The key targets in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market are Glucagon Like Peptide 1 Receptor, Thyroid Hormone Receptor Beta, Glucagon Receptor, Peroxisome Proliferator Activated Receptor Alpha, Bile Acid Receptor, Diacylglycerol O Acyltransferase 2, Toll Like Receptor 4, Fibroblast Growth Factor Receptor 1 and others.
-
What are the key mechanisms of action in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market?
The key mechanisms of action in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market are Glucagon Like Peptide 1 Receptor Agonist, Thyroid Hormone Receptor Beta Agonist, Bile Acid Receptor Agonist, Toll Like Receptor 4 Antagonist, Acyl CoA Desaturase Inhibitor, Cannabinoid Receptor 1 Antagonist, and many others.
-
What are the key routes of administration in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market?
The key routes of administration in the Non Alcoholic Fatty Liver Disease (NAFLD)pipeline products market are intramuscular, vaginal, oral, parenteral, intravenous, subcutaneous, topical, and sublingual.
-
What are the key molecule types in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market?
The key molecule types in the Non Alcoholic Fatty Liver Disease (NAFLD)pipeline products market are small molecule, peptide, recombinant protein, antisense oligonucleotide, biologic, monoclonal antibody, recombinant peptide, synthetic peptide, fusion protein, and gene therapy.
-
What are the major companies in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market?
The major companies in the Non Alcoholic Fatty Liver Disease (NAFLD)pipeline products market are  Pfizer Inc, Novartis AG, 89bio Inc, ABIONYX Pharma SA, Amgen Inc (Amgen), Ascletis Pharma Inc (Ascletis Pharma), AstraZeneca Plc, and Betagenon AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports